GLYCIPHAGE® Tablets
Composition:
GLYCIPHAGE® 500 mg:
Each uncoated tablet contains:
- Metformin Hydrochloride I.P. ………………………………………………………… 500 mg
- Excipients.......................................…............................................................... q.s.
GLYCIPHAGE® 850 mg:
Each uncoated tablet contains:
- Metformin Hydrochloride I.P. ………………………………………………………… 850 mg
- Excipients.......................................…...........................................................…. q.s.
GLYCIPHAGE® 250 mg:
Each uncoated tablet contains:
- Metformin Hydrochloride I.P. …………………………………………………………. 250 mg
- Excipients................................…...................................................................…. q.s.
Description
- GLYCIPHAGE is an oral anti-diabetic drug belonging to the biguanide group. Metformin is not chemically or pharmacologically related to Sulphonylureas, Thiazolidinediones, Gliptins, SGLT2 inhibitors or Alpha-glucosidase inhibitors. Metformin hydrochloride improves glucose tolerance by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, inhibiting gluconeogenesis and improving insulin sensitivity by increasing peripheral glucose uptake and utilization.
Indications
- Type 2 diabetic patients not responding to dietary regulations and physical exercise, should be put on GLYCIPHAGE® as the first line treatment.
- In IGT (Impaired Glucose Tolerance).
- In combination with insulin secretagogues, glitazones and adjuvant to insulin therapy.
- In PCOS (Polycystic Ovary Syndrome).
- In essential hypertension.